Where Will Eli Lilly Be in 10 Years?

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
Drug Store News

Eli Lilly lowers price of Zepbound single-dose vials

With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per ...

Lilly Cuts Low-Dose Zepbound Price for Cash-Pay Buyers

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...

Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...
ABC Columbia

Eli Lily cuts price for Zepbound

Monday, Dec. 1, Eli Lilly announced Zepbound will cost less for those who buy the medication straight from the drugmaker. This comes a couple of weeks after rival Novo Nordisk said it would drop the ...
The Economist

The plan to rescue Denmark’s weight-loss pioneer

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...
Devdiscourse

Race in Obesity Drugs Heats Up Amidst Legal Battles and Aid Crises

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...